Glenmark Pharmaceuticals: The Price, the Supply and Who Gets the Customer

In the Glenmark pravastatin price fixing case, the manufacturer agreed to pay $25 million to resolve allegations that it paid and received compensation through arrangements with competitors on price, supply and customers. For someone in generic-drug sales, that puts the focus on familiar decisions: who sets the price, who gets the account and what competitors have promised one another.

The Department of Justice announced the civil False Claims Act settlement on September 4, 2024. Glenmark Pharmaceuticals Inc., USA is a generic drug manufacturer in Mahwah, New Jersey. The allegations covered 2013 through 2015 and concerned pravastatin, widely used to treat high cholesterol and triglyceride levels.

This pharmaceutical fraud case reaches into the commercial decisions behind the prescription. The government’s allegation was that competing manufacturers compensated one another through arrangements that interfered with competition. The federal health programs paying for the drug had a stake in those arrangements too.

Are Generic Drugs Causing Inflated Prices?

Agreements among generic-drug manufacturers can inflate prices by restricting competition on price, supply and customers. That is what the government alleged happened with Glenmark’s pravastatin. Those details matter because competition depends on a buyer being able to take its business elsewhere.

Generic purchasing brings together wholesalers and major pharmacy or retail businesses. McKesson’s fiscal 2026 annual report describes sourcing generic drugs through ClarusONE, its joint venture with Walmart. Cencora’s fiscal 2025 annual report describes an arrangement under which Walgreens Boots Alliance Development negotiates acquisition prices with generic manufacturers on its behalf. Those buyers negotiate before the drug reaches a pharmacy. A manufacturer agreeing with a rival about which customers to pursue can undermine competition at that purchasing stage.

Under the government’s theory, agreeing on customers helps protect the agreed price. A rival that leaves an account alone removes a buyer’s opportunity to play competing offers against one another. An arrangement about supply can serve the same bargain. A salesperson may recognize the account decision before anyone describes it as price fixing.

Why the Government Treated Competitor Deals as Kickbacks

The civil case connected the manufacturers’ alleged arrangements to government purchases through the Anti-Kickback Statute and the False Claims Act. The Department of Justice alleged that Glenmark both paid and received prohibited compensation through the price, supply and customer-allocation arrangements.

The Anti-Kickback Statute prohibits companies from making or receiving payments in return for arranging purchases of drugs that federal health care programs may pay for. Here, the kickback allegation concerned arrangements among drug manufacturers.

Patients needing the drug and taxpayers funding Medicare and TRICARE bear the cost of inflated prices. The announcement identifies both programs among those the agencies sought to protect. The pricing decision begins inside a company. The bill reaches a public healthcare program.

The Civil Settlement and the Apotex Parallel

The Justice Department based Glenmark’s settlement on its ability to pay.

Apotex’s pravastatin settlement, announced on October 1, 2021, provides a close parallel. Apotex agreed to a $49 million civil False Claims Act settlement over alleged arrangements to increase and maintain pravastatin prices and resulting federal-program overpayments.

The connection is the same drug and the same path from a manufacturer’s commercial arrangement to a government payment. For an insider, that keeps the inquiry focused on what the companies agreed, how that agreement affected sales and which public programs paid.

What the Later State Settlement Added

On July 15, 2026, the New York Attorney General announced a separate multistate Glenmark settlement of more than $29 million. The funds will go to affected consumers across the coalition states.

The state settlement also reached the company’s future sales practices. Glenmark agreed to internal reforms, including an antitrust compliance program and annual training for sales and management staff.

The states’ broader lawsuits alleged a coordinated effort to fix prices, avoid competition and rig bids across more than 100 generic drugs. The announcement says that in some instances coordinated price increases exceeded 1,000 percent. According to the announcement, competing executives met at industry dinners, lunches, cocktail parties and golf outings, and communicated through frequent calls, emails and text messages. The states alleged that those contacts helped build the agreements.

The announcement also describes how defendants in the broader litigation allegedly talked about competition:

That language makes accommodation between competitors sound like good behavior. The states alleged that it was a way to discourage competition and raise prices. For someone reading an account instruction inside a company, the understanding behind the polite wording can be the important part.

What Pricing and Sales Employees Can Show

An insider’s contribution is the connection between a competitor conversation, a commercial decision and the business that followed. In this case, the government’s allegations identify the subjects of that connection: price, supply and allocation of customers.

We examine pricing communications alongside the prices actually charged. The useful detail is the relationship between the conversation and the decision: which drug and account were discussed, what was agreed and how the company acted afterward. An employee who understands the pricing process may be able to explain why a particular instruction mattered.

Customer and supply records add another view. We compare account instructions and supply terms with communications between manufacturers. The question is whether the company was carrying out an understanding with a rival about who would supply a buyer or pursue its business. Sales and contracting knowledge can make that relationship visible.

The payment side completes the picture. A manufacturer sells into a distribution chain, while the government’s interest concerns the health care spending tied to the drug. We work with the insider to connect the commercial records to the affected purchases and federal-program payments. That is where knowledge of the business becomes useful to a False Claims Act case.

For pharmaceutical whistleblowers, a case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know Why the Account Was Left Alone

If you know how a competitor conversation changed a price, a supply commitment or the pursuit of a customer, talk with our whistleblower experts about what happened inside the business. We build the case with you, bring in pharmaceutical whistleblower lawyers who understand competitor pricing agreements and federal drug payments, and stay beside you throughout the case.